CA3074541C - Compositions de suppression de l`appetit et methodes connexes - Google Patents

Compositions de suppression de l`appetit et methodes connexes Download PDF

Info

Publication number
CA3074541C
CA3074541C CA3074541A CA3074541A CA3074541C CA 3074541 C CA3074541 C CA 3074541C CA 3074541 A CA3074541 A CA 3074541A CA 3074541 A CA3074541 A CA 3074541A CA 3074541 C CA3074541 C CA 3074541C
Authority
CA
Canada
Prior art keywords
various embodiments
composition
appetite suppressant
appetite
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3074541A
Other languages
English (en)
Other versions
CA3074541A1 (fr
Inventor
Suzanne Bentz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Red Mountain Med Spa LLC
Original Assignee
Red Mountain Med Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Mountain Med Holdings LLC filed Critical Red Mountain Med Holdings LLC
Priority to CA3175950A priority Critical patent/CA3175950A1/fr
Priority to CA3074541A priority patent/CA3074541C/fr
Publication of CA3074541A1 publication Critical patent/CA3074541A1/fr
Application granted granted Critical
Publication of CA3074541C publication Critical patent/CA3074541C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon divers modes de réalisation, une composition de suppression de lappétit comprend au moins un ingrédient actif anorexigène; une substance nutritive, un agent dapport de médicament régulé et/ou un cofacteur; et, facultativement, un excipient. Lingrédient actif anorexigène peut comprendre lun ou lautre de phentermine, phendimétrazine, diéthylpropion, naltrexone et bupropion. Lagent dapport de médicament régulé peut comprendre un cellulosique. Le cofacteur peut comprendre un sel de chrome ou sélénium. Selon divers modes de réalisation, les compositions dans la présente sont fournies dans une forme de dosage de capsule orale pour ladministration, dans le tractus gastro-intestinal, de lingrédient actif anorexigène. Il est décrit une méthode de suppression de lappétit chez des individus qui en ont besoin.
CA3074541A 2020-03-03 2020-03-03 Compositions de suppression de l`appetit et methodes connexes Active CA3074541C (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3175950A CA3175950A1 (fr) 2020-03-03 2020-03-03 Compositions de suppression de l`appetit et methodes connexes
CA3074541A CA3074541C (fr) 2020-03-03 2020-03-03 Compositions de suppression de l`appetit et methodes connexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3074541A CA3074541C (fr) 2020-03-03 2020-03-03 Compositions de suppression de l`appetit et methodes connexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3175950A Division CA3175950A1 (fr) 2020-03-03 2020-03-03 Compositions de suppression de l`appetit et methodes connexes

Publications (2)

Publication Number Publication Date
CA3074541A1 CA3074541A1 (fr) 2021-09-03
CA3074541C true CA3074541C (fr) 2023-06-20

Family

ID=77554587

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3074541A Active CA3074541C (fr) 2020-03-03 2020-03-03 Compositions de suppression de l`appetit et methodes connexes
CA3175950A Pending CA3175950A1 (fr) 2020-03-03 2020-03-03 Compositions de suppression de l`appetit et methodes connexes

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3175950A Pending CA3175950A1 (fr) 2020-03-03 2020-03-03 Compositions de suppression de l`appetit et methodes connexes

Country Status (1)

Country Link
CA (2) CA3074541C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023148234A1 (fr) * 2022-02-04 2023-08-10 Rousselot Bv Utilisation d'hydrolysat de collagène dans la prévention et/ou le traitement d'une envie alimentaire
WO2023213909A1 (fr) 2022-05-04 2023-11-09 Rousselot Bv Composition d'hydrolysat de collagène pour réduire des douleurs articulaires après un exercice

Also Published As

Publication number Publication date
CA3074541A1 (fr) 2021-09-03
CA3175950A1 (fr) 2021-09-03

Similar Documents

Publication Publication Date Title
US12303514B2 (en) Immediate and controlled release appetite suppressant compositions for weight loss
KR20190005823A (ko) 제어된-방출 및 혼층 사이클로덱스트린 내포 복합체 비히클
CN103300278B (zh) 含有咪唑肽和槲皮素糖苷的组合物
JP6460998B2 (ja) トコトリエノールの経粘膜送達
US20240299292A1 (en) Stable semi-solid chewable gel compositions and methods of making and using thereof
WO2012142413A2 (fr) Compositions à base de nitrite et leurs utilisations
JP2011502132A (ja) 改善された錠剤コーティング
CA3074541C (fr) Compositions de suppression de l`appetit et methodes connexes
CN116568312A (zh) 稳定的半固体可咀嚼凝胶组合物及其制作和使用方法
CN104840800B (zh) 竹叶黄酮与γ-氨基丁酸的组合物及其制备方法和应用
KR20200107809A (ko) 자일리톨 및/또는 효소처리 스테비아로 피복된 복합비타민 과립제
WO2009123029A1 (fr) Régulateur de niveau d’ammoniac dans le sang
KR20040032821A (ko) 아데노신 트리포스페이트의 투여를 통한 근육 피로의 감소방법
US12551470B2 (en) Metabolism enhancing compositions
CN106880599B (zh) 含多单位载体的固态软式口溶锭
CN205411710U (zh) 含多单位载体的固态软式口溶锭
TW201720429A (zh) 含多單位載體的固態軟式口溶錠
TWM513700U (zh) 含多單位活性載體的口香糖
TW201703639A (zh) 含多單位活性載體的口香糖

Legal Events

Date Code Title Description
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250904

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251109